3D4 Pedia: a “printed” medication tailored to patients’ needs

The collaboration between laboratories atthe University of Montpellier (UM) and MB Therapeutics is paving the way for a new generation of personalized treatments: thanks to 3D printing technology that has been in development for several years, the 3D4 Pedia project could revolutionize drug therapy for young patients.

A major breakthrough in pediatric medicine, driven by innovation in Montpellier and the expertise of a pioneering industry leader, supported by the Companies and Campus program.

Read the full article: 3D4 Pedia – a 3D-printed medication tailored to patients’ needs

Ian SOULAIROL, researcher at the ICGM (Institut Charles Gerhardt Montpellier),
co-founder of MB Therapeutics, and head of the drug production unit at Nîmes University Hospital